Caribou Biosciences (CRBU) announced positive results from its ongoing ANTLER phase 1 clinical trial evaluating vispacabtagene regedleucel, vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort and with longer-term follow-up on patients who received optimized vispa-cel: 82% ORR, 64% CR rate, 51% PFS at 12 months in patients prospectively enrolled in partial HLA matching confirmatory cohort, 86% ORR, 63% CR rate, 53% PFS at 12 months in patients who received vispa-cel with an optimized profile
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBU:
- Caribou Biosciences’ CRISPR-Edited CAR-T Therapy: A Promising Step in Multiple Myeloma Treatment
- Caribou Biosciences’ Long-Term Study: A Key Update for Investors
- Video: This stock is dragging down the in vivo gene editing therapy space
- Caribou Biosciences Advances CRISPR-Edited CAR-T Therapy in Lymphoma Study
- Intellia Therapeutics price target lowered to $30 from $36 at BofA